Russ Conroy

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.

Phase 1b data support the potential benefits of R289 as a treatment for patients with lower-risk myelodysplastic syndrome.

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Investigators of a phase 2a trial plan to include additional combination arms assessing treatment with IMM-1-104 across different patient populations.

Data suggest a need for international preventive strategies and educational efforts regarding the increasing incidence of early-onset colorectal cancer.

Data from a phase 1b/2 trial show improvements in overall survival with amezalpat plus atezolizumab/bevacizumab among patients with metastatic HCC.

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.

Findings from the phase 3 SACHI trial support the National Medical Products Administration’s priority review designation for savolitinib/osimertinib.

Treatment with satricabtagene autoleucel met the primary end point of progression-free survival in the phase 2 CT041-ST-01 trial.

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

Phase 1b/2 data show antitumor activity with zanidatamab/evorpacept, including among heavily pretreated patients with HER2-low metastatic breast cancer.

Phase 2 data indicate that CD8 status may serve as a biomarker for predicting treatment efficacy with tislelizumab-based treatment in TNBC.

Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.

Meta-analysis data show moderate decreases in distant recurrence and breast cancer mortality with immediate surgery after longer follow-up.

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.

A panel of cancer survivorship experts outline major areas of focus and care models for improving outcomes among pediatric and adult survivors of cancer.

The IPSS-del(5q) Scoring System shows that factors including male sex, cytopenias, and complex genetic background worsen the prognosis of MDS-del(5q).

The launch of this pazopanib tablet formulation for patients with RCC or sarcoma is anticipated in the fourth quarter of 2025.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

Data from the phase 2/3 KEYNOTE-483 trial support the CHMP’s recommendation for approving pembrolizumab/chemotherapy in the European Union.

Data from the phase 2b ReNeu trial may support mirdametinib as a valuable new treatment option for adults and children with NF1-PN.

Survival data from the interim analysis of the phase 3 DREAMM-7 trial will be presented at the 2024 ASH Annual Meeting.